530 related articles for article (PubMed ID: 26378938)
1. The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.
Gemzell-Danielsson K; Apter D; Hauck B; Schmelter T; Rybowski S; Rosen K; Nelson A
PLoS One; 2015; 10(9):e0135309. PubMed ID: 26378938
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
Gemzell-Danielsson K; Apter D; Dermout S; Faustmann T; Rosen K; Schmelter T; Merz M; Nelson A
Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():22-28. PubMed ID: 27930941
[TBL] [Abstract][Full Text] [Related]
3. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents.
Gemzell-Danielsson K; Buhling KJ; Dermout SM; Lukkari-Lax E; Montegriffo E; Apter D
Contraception; 2016 Jun; 93(6):507-12. PubMed ID: 26872720
[TBL] [Abstract][Full Text] [Related]
4. A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population.
Fan G; Kang S; Ren M; Weisberg E; Lukkari-Lax E; Roth K; Shin S
Contraception; 2017 Apr; 95(4):371-377. PubMed ID: 27913229
[TBL] [Abstract][Full Text] [Related]
5. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
6. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS.
Wildemeersch D; Goldstuck ND; Jackers G
Gynecol Endocrinol; 2017 Mar; 33(3):223-226. PubMed ID: 28084114
[TBL] [Abstract][Full Text] [Related]
7. The levonorgestrel intrauterine system in nulliparous women.
Prager S; Darney PD
Contraception; 2007 Jun; 75(6 Suppl):S12-5. PubMed ID: 17531602
[TBL] [Abstract][Full Text] [Related]
8. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
9. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
[TBL] [Abstract][Full Text] [Related]
10. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems.
Wildemeersch D; Janssens D; Vrijens M; Weyers S
Contraception; 2005 Jun; 71(6):465-9. PubMed ID: 15914138
[TBL] [Abstract][Full Text] [Related]
11. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
[TBL] [Abstract][Full Text] [Related]
12. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial.
Nelson A; Apter D; Hauck B; Schmelter T; Rybowski S; Rosen K; Gemzell-Danielsson K
Obstet Gynecol; 2013 Dec; 122(6):1205-13. PubMed ID: 24240244
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies.
Apter D; Gemzell-Danielsson K; Hauck B; Rosen K; Zurth C
Fertil Steril; 2014 Jun; 101(6):1656-62.e1-4. PubMed ID: 24726226
[TBL] [Abstract][Full Text] [Related]
14. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.
Gemzell-Danielsson K; Schellschmidt I; Apter D
Fertil Steril; 2012 Mar; 97(3):616-22.e1-3. PubMed ID: 22222193
[TBL] [Abstract][Full Text] [Related]
15. Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use.
Darney PD; Stuart GS; Thomas MA; Cwiak C; Olariu A; Creinin MD
Contraception; 2018 Mar; 97(3):210-214. PubMed ID: 29038072
[TBL] [Abstract][Full Text] [Related]
16. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.
Eisenberg DL; Schreiber CA; Turok DK; Teal SB; Westhoff CL; Creinin MD;
Contraception; 2015 Jul; 92(1):10-6. PubMed ID: 25934164
[TBL] [Abstract][Full Text] [Related]
17. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
18. Pain at insertion of the levonorgestrel-releasing intrauterine system in nulligravida and parous women with and without cesarean section.
Santos AR; Bahamondes MV; Hidalgo MM; Atti A; Bahamondes L; Monteiro I
Contraception; 2013 Jul; 88(1):164-8. PubMed ID: 23507169
[TBL] [Abstract][Full Text] [Related]
19. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
Nelson AL
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):833-842. PubMed ID: 28617060
[TBL] [Abstract][Full Text] [Related]
20. Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy.
Graner S; Mc Taggart J; Nordström F; Melander E; Widenberg J; Kopp Kallner H
Acta Obstet Gynecol Scand; 2019 Jul; 98(7):937-943. PubMed ID: 30737766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
